Alpha one antitrypsin deficiency: From gene to treatment

Research output: Contribution to journalReview articlepeer-review


Colleges, School and Institutes


α1-antitrypsin deficiency is a genetic disorder which contributes to the development of chronic obstructive pulmonary disease, bronchiectasis, liver cirrhosis and panniculitis. The discovery of α1-antitrypsin and its function as an antiprotease led to the protease-antiprotease hypothesis, which goes some way to explaining the pathogenesis of emphysema. This article will review the clinical features of α1-antitrypsin deficiency, the genetic mutations known to cause it, and how they do so at a molecular level. Specific treatments for the disorder based on this knowledge will be reviewed, including α1-antitrypsin replacement, gene therapy and possible future therapies, such as those based on stem cells.


Original languageEnglish
Pages (from-to)481-492
Number of pages12
Issue number5
Publication statusPublished - 1 Aug 2007


  • biological therapy, epidemiology, molecular, genetics, population, molecular biology, alpha 1-antitrypsin deficiency